Drug Discovery & Pharmaceuticals

RSS

Solving a 50-year Bottleneck in Chemotherapy Drug Production

A multinational team of researchers has made a significant advance in the manufacturing of doxorubicin, a crucial chemotherapy drug.

16 Mar 2026

mAbxience Selects Genedata Bioprocess to Automate End-to-End CDMO Workflows

Genedata, a Danaher company and the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that mAbxience has selected the Genedata Bioprocess® enterprise platform to structure and harmonize all bioprocess development data across its operations.

From Genedata AG 11 Mar 2026

New AI Tool Guides Chemists Toward Faster Drug Discovery

Drug discovery is like molecular Tetris. Chemists snap atoms together, adjusting the pieces until everything fits and suddenly, a molecule makes a promising new medicine.

10 Mar 2026

A New Framework for High-Efficiency Drug Development

A research team under the direction of the Medical University of Vienna has identified a potential new method for drug development in a recently published review.

9 Mar 2026

Bacteria-Powered Drug Discovery: A Greener Path to Curing "Undruggable" Cancers

Researchers at the University of Bath have developed a new technology that uses bacteria to build, chemically stabilize, and test millions of potential drug molecules inside living cells, making it much quicker and easier to discover new treatments for difficult-to-treat cancers.

4 Mar 2026

Tirzepatide Reduces Alcohol Drinking And Relapse In Preclinical Study

Tirzepatide alters brain reward signaling and reduces alcohol intake in rodents, indicating its potential as a therapeutic option for alcohol use disorder.

4 Mar 2026

Promega Unveils Cellular Target Engagement Technology Aimed at Expanding the Druggable Proteome at SLAS 2026

Promega Corporation is launching a new live-cell target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins.

27 Feb 2026

Machine Learning Enhances Manufacturing of Complex Protein Drugs

Industrial yeasts are a powerhouse of protein production, used to manufacture vaccines, biopharmaceuticals, and other useful compounds.

18 Feb 2026

New Antibodies Prevent EBV Infection in Humanized Mouse Models

Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein Barr virus (EBV), a pathogen estimated to infect 95% of the global population that is linked to multiple types of cancer, neurodegenerative diseases and other chronic health conditions.

18 Feb 2026

Microbial Engineering Breakthrough Improves Supply of Promising Pharmaceuticals

Bioengineered E. coli bacteria can now produce a group of compounds with anticancer, anti-HIV, antidiabetic and anti-inflammatory activities.

18 Feb 2026

Mapping the Binding Energy of Histamine Receptors

G-protein-coupled receptors (GPCRs) are one of the biggest groups of cell surface proteins in the human body, recognizing hormones, neurotransmitters, and drugs.

16 Feb 2026

Machine Learning Model Accelerates Manufacturing Timeline of Monoclonal Antibodies

As instigators of immunity, monoclonal antibodies are marvels of modern medicine, lab-made proteins that can treat cancers, autoimmune diseases, and many other conditions.

10 Feb 2026

Understanding Inter-Micellar Interactions Governing Drug Nanocarriers

Polymer micelles are tiny, self-assembled particles that are revolutionizing the landscape of drug delivery and nanomedicine.

10 Feb 2026

DNA Origami Vaccine Scaffolds Sharpen Immune Targeting Against HIV

One of the biggest hurdles in developing an HIV vaccine is coaxing the body to produce the right kind of immune cells and antibodies. In most vaccines, HIV proteins are attached to a larger protein scaffolding that mimics a virus.

6 Feb 2026

Rapid Enzyme Screening Unlocks Efficient Routes to Complex Pharmaceuticals

A team of biochemists at the University of California, Santa Cruz, has developed a faster way to identify molecules in the lab that could lead to more effective pharmaceuticals.

6 Feb 2026

Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026

Revvity, Inc. announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows.

5 Feb 2026

New Boron Compounds Enable Easier Drug Modification Without Breakdown

A major step towards simpler drug development has been taken at the University of Gothenburg. In a new study, researchers have developed stable boron-fluorine compounds that make it possible to increase the effect or reduce side effects without breaking down the medicine.

4 Feb 2026

Dr Adam Davenport Appointed as CSO to Strengthen Leadership in Integrated Drug Discovery

We are pleased to announce the appointment of Dr Adam Davenport as Chief Scientific Officer to spearhead our integrated drug discovery offering for biotech and pharmaceutical partners.

From Concept Life Sciences 19 Jan 2026

Synthetic Biology and Metabolic Engineering Drive Microbial L-Tryptophan Biomanufacturing

This review synthesizes progress in pathway optimization, regulatory rewiring, and microbial cell factory design that has driven L-Trp titers to industrially relevant levels while enabling the biosynthesis of downstream products ranging from neurotransmitters and plant hormones to dyes and complex alkaloids.

8 Jan 2026

MD Anderson and SOPHiA GENETICS Partner to Advance AI-Driven Cancer Care

The University of Texas MD Anderson Cancer Center and SOPHiA GENETICS today announced a strategic collaboration that unites SOPHiA GENETICS' AI-powered analytics with MD Anderson's clinical and scientific expertise to accelerate data-driven cancer care through new tools that can accurately analyze, interpret and translate diagnostic results into clinical practice.

8 Jan 2026